CAS NO: | 110101-67-2 |
包装: | 50mg, 100mg, 250mg |
规格: | ≥98% |
Tirilazad, formerly known as U 74006F, is a lazaroid and potent inhibitor of iron-dependent lipid peroxidation. Tirilazad has shown excellent activity in in vivo models of experimental central nervous system trauma & ischemia. Tirilazad is a drug that has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being. Tirilazad currently has no usage in the clinical treatment of stroke. References: Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA. 1997 May 28;277(20):1597-604. PubMed PMID: 9168289.
纯度:≥98%
CAS:110101-67-2